Your search for ‘Cornerstone Research’ returned 107 results

Since the start of 2018, state and, to a lesser extent, federal courts around the country, as well as state legislatures and Congress,

Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology...

Securities class action lawsuits have long been a fact of life for public companies traded on a U.S. exchange.

In 2024, plaintiffs filed 36 securities class action lawsuits against non-U.S. issuers, up by three from the 33 filings in 2023.

Securities class action filings remained elevated in 2025, signaling that robust activity will likely persist into 2026. According to economic and financial consulting company Cornerstone Research...